Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020
The cancer industry is one of the most lucrative business worldwide. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Cancer vaccines can be broadly classified into two segments: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer. With the rising incidences of cancer and limited treatment options, physicians are being forced to look for precautionary vaccines beyond the conventional treatments. As a result, many companies are now investing in developing prophylactic and therapeutic vaccines to curb this deadly disease.
The prophylactic vaccines currently available in the market include Mercks Gardasil and GSKs Cervarix while the only therapeutic vaccine in the market is Dendreon's Provenge. In the global cancer vaccines market, the prophylactic vaccines segment account for maximum share of the market. However, the market share of prophylactic vaccines is likely to decline continuously during the forecasting period due to the increasing uptake of therapeutic vaccines. The market share of therapeutic cancer vaccines is anticipated to increase during the forecasting period.
In the cancer vaccines market, Merck is the clear leader and is expected to maintain its dominancy over a longer period of time. Dendreon Corporation is the second leading player in cancer vaccines market accounting for XX% market share in 2014. It is predicted that GSK will account for single digit share of the cancer vaccine market by 2020.
Global Cancer Vaccines Market - Regional Analysis: The United States is the largest regional market for cancer vaccines. United States accounted for XX% share of the global cancer vaccines market in 2014. The Asian region is the second leading market for cancer vaccines. The European region cancer vaccines market share is anticipated to increase from XX% in 2014 to XX% by the year 2020.
iGATE Research report titled Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020 is a 213 page report with 26 Figures and 25 Tables. This report studies in detail the Global Cancer Vaccines Market, Regional Cancer Vaccines Market, Major Deals and Funding in Cancer Vaccines Industry, Cancer Vaccines Pipeline Products Portfolio, Company Wise Cancer Vaccines Pipeline Products and the driving factors and challenges for the Cancer Vaccines Market.
The Cancer Vaccines Market studied in the report covers the following 7 points:
1. Global - Prophylactic Cancer Vaccines Market to 2020
I. Gardasil
II. Cervarix
2. Global - Therapeutic Cancer Vaccines Market to 2020
I. Provenge
3. Cancer Vaccines Market - Regional Analysis to 2020
I. United States - Cancer Vaccines Market
II. Europe - Cancer Vaccines Market
III. Asia - Cancer Vaccines Market
4. Global Cancer Vaccines Market - Major Deals
5. Global Cancer Vaccines - Funding
6. Global Cancer Vaccines Market - Pipeline Portfolio Analysis
7. Company Cancer Vaccines - Pipeline Analysis
The 12 Cancer Vaccines Pipeline Portfolio covered in the report are as follows
1. Prostvac
2. Neuvax
3. Rindopepimut
4. MVax
5. DCVax-L
6. ProstAtak
7. Talimogene Laherparepvec
8. IMA901
9. Imprime PGG
10. OncoVAX
11. Lucanix
12. DCVAC/PCa
The 34 Companies Pipeline Cancer Vaccines covered in the reports are as follows:
1. Aduro Biotech
2. Advantagene
3. Advaxis
4. Agenus
5. AlphaVax
6. Altor BioScience
7. Argos Therapeutics
8. AVAX Technologies
9. Bavarian Nordic
10. Biothera
11. Celldex Therapeutics
12. CureVac
13. Galena Biopharma
14. Genexine
15. GlobeImmune
16. Gradalis
17. Heat Biologics
18. Immatics
19. ImmunoCellular Therapeutics
20. Inovio Pharmaceuticals
21. ISA Pharmaceuticals
22. Juvaris Biotherapeutics
23. NewLink Genetics
24. Northwest Biotherapeutics
25. NovaRx
26. OncoThyreon
27. Oncovir
28. Oxford BioMedica
29. Prima BioMed
30. Sotio
31. Transgene
32. Ubivac
33. Vaccinogen
34. Vaxon Biotech
Source of Information
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.
Research Methodologies
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.
The prophylactic vaccines currently available in the market include Mercks Gardasil and GSKs Cervarix while the only therapeutic vaccine in the market is Dendreon's Provenge. In the global cancer vaccines market, the prophylactic vaccines segment account for maximum share of the market. However, the market share of prophylactic vaccines is likely to decline continuously during the forecasting period due to the increasing uptake of therapeutic vaccines. The market share of therapeutic cancer vaccines is anticipated to increase during the forecasting period.
In the cancer vaccines market, Merck is the clear leader and is expected to maintain its dominancy over a longer period of time. Dendreon Corporation is the second leading player in cancer vaccines market accounting for XX% market share in 2014. It is predicted that GSK will account for single digit share of the cancer vaccine market by 2020.
Global Cancer Vaccines Market - Regional Analysis: The United States is the largest regional market for cancer vaccines. United States accounted for XX% share of the global cancer vaccines market in 2014. The Asian region is the second leading market for cancer vaccines. The European region cancer vaccines market share is anticipated to increase from XX% in 2014 to XX% by the year 2020.
iGATE Research report titled Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020 is a 213 page report with 26 Figures and 25 Tables. This report studies in detail the Global Cancer Vaccines Market, Regional Cancer Vaccines Market, Major Deals and Funding in Cancer Vaccines Industry, Cancer Vaccines Pipeline Products Portfolio, Company Wise Cancer Vaccines Pipeline Products and the driving factors and challenges for the Cancer Vaccines Market.
The Cancer Vaccines Market studied in the report covers the following 7 points:
1. Global - Prophylactic Cancer Vaccines Market to 2020
I. Gardasil
II. Cervarix
2. Global - Therapeutic Cancer Vaccines Market to 2020
I. Provenge
3. Cancer Vaccines Market - Regional Analysis to 2020
I. United States - Cancer Vaccines Market
II. Europe - Cancer Vaccines Market
III. Asia - Cancer Vaccines Market
4. Global Cancer Vaccines Market - Major Deals
5. Global Cancer Vaccines - Funding
6. Global Cancer Vaccines Market - Pipeline Portfolio Analysis
7. Company Cancer Vaccines - Pipeline Analysis
The 12 Cancer Vaccines Pipeline Portfolio covered in the report are as follows
1. Prostvac
2. Neuvax
3. Rindopepimut
4. MVax
5. DCVax-L
6. ProstAtak
7. Talimogene Laherparepvec
8. IMA901
9. Imprime PGG
10. OncoVAX
11. Lucanix
12. DCVAC/PCa
The 34 Companies Pipeline Cancer Vaccines covered in the reports are as follows:
1. Aduro Biotech
2. Advantagene
3. Advaxis
4. Agenus
5. AlphaVax
6. Altor BioScience
7. Argos Therapeutics
8. AVAX Technologies
9. Bavarian Nordic
10. Biothera
11. Celldex Therapeutics
12. CureVac
13. Galena Biopharma
14. Genexine
15. GlobeImmune
16. Gradalis
17. Heat Biologics
18. Immatics
19. ImmunoCellular Therapeutics
20. Inovio Pharmaceuticals
21. ISA Pharmaceuticals
22. Juvaris Biotherapeutics
23. NewLink Genetics
24. Northwest Biotherapeutics
25. NovaRx
26. OncoThyreon
27. Oncovir
28. Oxford BioMedica
29. Prima BioMed
30. Sotio
31. Transgene
32. Ubivac
33. Vaccinogen
34. Vaxon Biotech
Source of Information
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.
Research Methodologies
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.
1. EXECUTIVE SUMMARY
2. GLOBAL - CANCER VACCINES MARKET AND FORECAST TO 2020
2.1 Global - Prophylactic Cancer Vaccines Market and Forecast to 2020
2.2 Global - Therapeutic Cancer Vaccines Market and Forecast to 2020
3. GLOBAL - CANCER VACCINES MARKET SHARE AND FORECAST TO 2020
3.1 Global Cancer Vaccines Market Share - By Type
3.2 Global Cancer Vaccines Market - Company Share Analysis
3.3 Cancer Vaccines Market - Regional Share Analysis
4. GLOBAL - PROPHYLACTIC CANCER VACCINES MARKET AND FORECAST TO 2020
4.1 Gardasil Sales and Forecast to 2020
4.2 Cervarix Sales and Forecast to 2020
5. GLOBAL - THERAPEUTICS CANCER VACCINES MARKET AND FORECAST TO 2020
5.1 Provenge Sales and Forecast to 2020
6. CANCER VACCINES MARKET - REGIONAL ANALYSIS
6.1 United States - Cancer Vaccines Market and Forecast to 2020
6.2 Europe - Cancer Vaccines Market and Forecast to 2020
6.3 Asia - Cancer Vaccines Market and Forecast to 2020
7. GLOBAL CANCER VACCINES MARKET - MAJOR DEALS
8. GLOBAL CANCER VACCINES - FUNDING
9. GLOBAL CANCER VACCINES MARKET - PIPELINE PORTFOLIO ANALYSIS
9.1 Prostvac
9.2 Neuvax
9.3 Rindopepimut
9.4 MVax
9.5 DCVax-L
9.6 ProstAtak
9.7 Talimogene Laherparepvec
9.8 IMA901
9.9 Imprime PGG
9.10 OncoVAX
9.11 Lucanix
9.12 DCVAC/PCa
10. COMPANY CANCER VACCINES - PIPELINE ANALYSIS
10.1 Aduro Biotech
10.2 Advantagene
10.3 Advaxis
10.4 Agenus
10.5 AlphaVax
10.6 Altor BioScience
10.7 Argos Therapeutics
10.8 AVAX Technologies
10.9 Bavarian Nordic
10.10 Biothera
10.11 Celldex Therapeutics
10.12 CureVac
10.13 Galena Biopharma
10.14 Genexine
10.15 GlobeImmune
10.16 Gradalis
10.17 Heat Biologics
10.18 Immatics
10.19 ImmunoCellular Therapeutics
10.20 Inovio Pharmaceuticals
10.21 ISA Pharmaceuticals
10.22 Juvaris Biotherapeutics
10.23 NewLink Genetics
10.24 Northwest Biotherapeutics
10.25 NovaRx
10.26 OncoThyreon
10.27 Oncovir
10.28 Oxford BioMedica
10.29 Prima BioMed
10.30 Sotio
10.31 Transgene
10.32 Ubivac
10.33 Vaccinogen
10.34 Vaxon Biotech
11. GLOBAL CANCER VACCINES MARKET - DRIVING FACTORS
11.1 Increasing Incidence of Cancer
11.2 GAVI Model Fuelling Vaccine Manufacturers
11.2.1 The Partnership Model
11.2.2 The Business Model
11.3 Global Immunization Vision and Strategy (GIVS)
11.4 Growing Vaccine Availability in United States
11.5 The Vaccine Injury Compensation Program
11.6 The Vaccine Safety Data link Project
11.7 Transformation of Vaccine Technologies
11.8 Global Vaccine Action Plan by WHO (2011 - 2020)
11.9 Continuous Focus on Effective Communication Strategies
12. GLOBAL CANCER VACCINES MARKET - CHALLENGES
12.1 Hurdles to Optimal use of Licensed Vaccines
12.1.1 Technical Obstacles
12.1.2 Economic obstacles
12.1.3 Cultural Obstacles
12.2 Shortening the Timeline for Vaccine Development
12.3 Complexity of Vaccine Development and Approval System Thwarts Product Development
12.3.1 Legal Obstacles
12.3.2 General Technical Barriers
12.3.3 Economic Barriers
12.3.4 Regulatory Barriers
12.4 Obstacles in Vaccine Research and Development
12.5 Barriers to New Entrants in the Vaccines Market
2. GLOBAL - CANCER VACCINES MARKET AND FORECAST TO 2020
2.1 Global - Prophylactic Cancer Vaccines Market and Forecast to 2020
2.2 Global - Therapeutic Cancer Vaccines Market and Forecast to 2020
3. GLOBAL - CANCER VACCINES MARKET SHARE AND FORECAST TO 2020
3.1 Global Cancer Vaccines Market Share - By Type
3.2 Global Cancer Vaccines Market - Company Share Analysis
3.3 Cancer Vaccines Market - Regional Share Analysis
4. GLOBAL - PROPHYLACTIC CANCER VACCINES MARKET AND FORECAST TO 2020
4.1 Gardasil Sales and Forecast to 2020
4.2 Cervarix Sales and Forecast to 2020
5. GLOBAL - THERAPEUTICS CANCER VACCINES MARKET AND FORECAST TO 2020
5.1 Provenge Sales and Forecast to 2020
6. CANCER VACCINES MARKET - REGIONAL ANALYSIS
6.1 United States - Cancer Vaccines Market and Forecast to 2020
6.2 Europe - Cancer Vaccines Market and Forecast to 2020
6.3 Asia - Cancer Vaccines Market and Forecast to 2020
7. GLOBAL CANCER VACCINES MARKET - MAJOR DEALS
8. GLOBAL CANCER VACCINES - FUNDING
9. GLOBAL CANCER VACCINES MARKET - PIPELINE PORTFOLIO ANALYSIS
9.1 Prostvac
9.2 Neuvax
9.3 Rindopepimut
9.4 MVax
9.5 DCVax-L
9.6 ProstAtak
9.7 Talimogene Laherparepvec
9.8 IMA901
9.9 Imprime PGG
9.10 OncoVAX
9.11 Lucanix
9.12 DCVAC/PCa
10. COMPANY CANCER VACCINES - PIPELINE ANALYSIS
10.1 Aduro Biotech
10.2 Advantagene
10.3 Advaxis
10.4 Agenus
10.5 AlphaVax
10.6 Altor BioScience
10.7 Argos Therapeutics
10.8 AVAX Technologies
10.9 Bavarian Nordic
10.10 Biothera
10.11 Celldex Therapeutics
10.12 CureVac
10.13 Galena Biopharma
10.14 Genexine
10.15 GlobeImmune
10.16 Gradalis
10.17 Heat Biologics
10.18 Immatics
10.19 ImmunoCellular Therapeutics
10.20 Inovio Pharmaceuticals
10.21 ISA Pharmaceuticals
10.22 Juvaris Biotherapeutics
10.23 NewLink Genetics
10.24 Northwest Biotherapeutics
10.25 NovaRx
10.26 OncoThyreon
10.27 Oncovir
10.28 Oxford BioMedica
10.29 Prima BioMed
10.30 Sotio
10.31 Transgene
10.32 Ubivac
10.33 Vaccinogen
10.34 Vaxon Biotech
11. GLOBAL CANCER VACCINES MARKET - DRIVING FACTORS
11.1 Increasing Incidence of Cancer
11.2 GAVI Model Fuelling Vaccine Manufacturers
11.2.1 The Partnership Model
11.2.2 The Business Model
11.3 Global Immunization Vision and Strategy (GIVS)
11.4 Growing Vaccine Availability in United States
11.5 The Vaccine Injury Compensation Program
11.6 The Vaccine Safety Data link Project
11.7 Transformation of Vaccine Technologies
11.8 Global Vaccine Action Plan by WHO (2011 - 2020)
11.9 Continuous Focus on Effective Communication Strategies
12. GLOBAL CANCER VACCINES MARKET - CHALLENGES
12.1 Hurdles to Optimal use of Licensed Vaccines
12.1.1 Technical Obstacles
12.1.2 Economic obstacles
12.1.3 Cultural Obstacles
12.2 Shortening the Timeline for Vaccine Development
12.3 Complexity of Vaccine Development and Approval System Thwarts Product Development
12.3.1 Legal Obstacles
12.3.2 General Technical Barriers
12.3.3 Economic Barriers
12.3.4 Regulatory Barriers
12.4 Obstacles in Vaccine Research and Development
12.5 Barriers to New Entrants in the Vaccines Market
LIST OF FIGURES:
Figure 2 1: Global - Cancer Vaccines Market (Million US$), 2007 - 2014
Figure 2 2: Global - Forecast for Cancer Vaccines Market (Million US$), 2015 - 2020
Figure 2 3: Global - Prophylactic Cancer Vaccines Market (Million US$), 2007 - 2014
Figure 2 4: Global - Forecast for Prophylactic Cancer Vaccines Market (Million US$), 2015 - 2020
Figure 2 5: Global - Therapeutic Cancer Vaccines Market (Million US$), 2011 - 2014
Figure 2 6: Global - Forecast for Therapeutic Cancer Vaccines Market (Million US$), 2015 - 2020
Figure 3 1: Global - Cancer Vaccines Market Share (Percent), 2011 - 2014
Figure 3 2: Global - Forecast for Cancer Vaccines Market Share (Percent), 2015 - 2020
Figure 3 3: By Company - Cancer Vaccines Market Share (Percent), 2011 - 2014
Figure 3 4: By Company - Forecast for Cancer Vaccines Market Share (Percent), 2015 - 2020
Figure 3 5: By Region - Cancer Vaccines Market Share (Percent), 2010 - 2014
Figure 3 6: By Region - Forecast for Cancer Vaccines Market Share (Percent), 2015 - 2020
Figure 4 1: Global - Gardasil Vaccines Sales (Million US$), 2007 - 2014
Figure 4 2: Global - Forecast for Gardasil Vaccines Sales (Million US$), 2015 - 2020
Figure 4 3: Global - Cervarix Vaccines Sales (Million US$), 2007 - 2014
Figure 4 4: Global - Forecast for Cervarix Vaccines Sales (Million US$), 2015 - 2020
Figure 5 1: Global - Provenge Vaccines Sales (Million US$), 2011 - 2014
Figure 5 2: Global - Forecast for Provenge Vaccines Sales (Million US$), 2015 - 2020
Figure 6 1: United States - Cancer Vaccines Market (Million US$), 2010 - 2014
Figure 6 2: United States - Forecast for Cancer Vaccines Market (Million US$), 2015 - 2020
Figure 6 3: Europe - Cancer Vaccines Market (Million US$), 2010 - 2014
Figure 6 4: Europe - Forecast for Cancer Vaccines Market (Million US$), 2015 - 2020
Figure 6 5: Asia - Cancer Vaccines Market (Million US$), 2010 - 2014
Figure 6 6: Asia - Forecast for Cancer Vaccines Market (Million US$), 2015 - 2020
Figure 11 1: Global - Estimated Number of Cancer Incidence Cases (Number), 2009 - 2015
Figure 11 2: US - Number of Retail Clinics offering Vaccination (Number), 2007 - 2012
Figure 2 1: Global - Cancer Vaccines Market (Million US$), 2007 - 2014
Figure 2 2: Global - Forecast for Cancer Vaccines Market (Million US$), 2015 - 2020
Figure 2 3: Global - Prophylactic Cancer Vaccines Market (Million US$), 2007 - 2014
Figure 2 4: Global - Forecast for Prophylactic Cancer Vaccines Market (Million US$), 2015 - 2020
Figure 2 5: Global - Therapeutic Cancer Vaccines Market (Million US$), 2011 - 2014
Figure 2 6: Global - Forecast for Therapeutic Cancer Vaccines Market (Million US$), 2015 - 2020
Figure 3 1: Global - Cancer Vaccines Market Share (Percent), 2011 - 2014
Figure 3 2: Global - Forecast for Cancer Vaccines Market Share (Percent), 2015 - 2020
Figure 3 3: By Company - Cancer Vaccines Market Share (Percent), 2011 - 2014
Figure 3 4: By Company - Forecast for Cancer Vaccines Market Share (Percent), 2015 - 2020
Figure 3 5: By Region - Cancer Vaccines Market Share (Percent), 2010 - 2014
Figure 3 6: By Region - Forecast for Cancer Vaccines Market Share (Percent), 2015 - 2020
Figure 4 1: Global - Gardasil Vaccines Sales (Million US$), 2007 - 2014
Figure 4 2: Global - Forecast for Gardasil Vaccines Sales (Million US$), 2015 - 2020
Figure 4 3: Global - Cervarix Vaccines Sales (Million US$), 2007 - 2014
Figure 4 4: Global - Forecast for Cervarix Vaccines Sales (Million US$), 2015 - 2020
Figure 5 1: Global - Provenge Vaccines Sales (Million US$), 2011 - 2014
Figure 5 2: Global - Forecast for Provenge Vaccines Sales (Million US$), 2015 - 2020
Figure 6 1: United States - Cancer Vaccines Market (Million US$), 2010 - 2014
Figure 6 2: United States - Forecast for Cancer Vaccines Market (Million US$), 2015 - 2020
Figure 6 3: Europe - Cancer Vaccines Market (Million US$), 2010 - 2014
Figure 6 4: Europe - Forecast for Cancer Vaccines Market (Million US$), 2015 - 2020
Figure 6 5: Asia - Cancer Vaccines Market (Million US$), 2010 - 2014
Figure 6 6: Asia - Forecast for Cancer Vaccines Market (Million US$), 2015 - 2020
Figure 11 1: Global - Estimated Number of Cancer Incidence Cases (Number), 2009 - 2015
Figure 11 2: US - Number of Retail Clinics offering Vaccination (Number), 2007 - 2012
LIST OF TABLES:
Table 9 1: NovaRx - Clinical Development Pipeline
Table 10 1: AlphaVax - Clinical Development Pipeline
Table 10 2: Altor BioScience - Clinical Development Pipeline
Table 10 3: Argos Therapeutics - Clinical Development Pipeline
Table 10 4: AVAX Technologies - Clinical Development Pipeline
Table 10 5: Biothera - Clinical Development Pipeline
Table 10 6: Celldex Therapeutics - Clinical Development Pipeline
Table 10 7: CureVac - Clinical Development Pipeline
Table 10 8: Genexine - Clinical Development Pipeline
Table 10 9: GlobeImmune - Clinical Development Pipeline
Table 10 10: Gradalis - Clinical Development Pipeline
Table 10 11: Heat Biologics - Clinical Development Pipeline
Table 10 12: ISA Pharmaceuticals - Clinical Development Pipeline
Table 10 13: ISA101-CervISA - Clinical Study Analysis
Table 10 14: NewLink Genetics - Clinical Development Pipeline
Table 10 15: Northwest Biotherapeutics - Clinical Development Pipeline
Table 10 16: NovaRx - Clinical Development Pipeline
Table 10 17: Sotio - Clinical Development Pipeline
Table 10 18: Transgene - Clinical Development Pipeline
Table 10 19: UbiVac - Clinical Development Pipeline
Table 10 20: Vaccinogen - ACTIVE Clinical Trial Analysis
Table 10 21: Vaxon Biotech - Clinical Developmet Pipeline
Table 11 1: Global - Total Future Deaths Averted through Vaccination (Million), 2011 - 2020
Table 11 2: Global Goal-Level Indicators, 2015 & 2020
Table 11 3: Improvement Strategies or Requirements - the Joint Commission and the Project’s Collaborating Organizations
Table 9 1: NovaRx - Clinical Development Pipeline
Table 10 1: AlphaVax - Clinical Development Pipeline
Table 10 2: Altor BioScience - Clinical Development Pipeline
Table 10 3: Argos Therapeutics - Clinical Development Pipeline
Table 10 4: AVAX Technologies - Clinical Development Pipeline
Table 10 5: Biothera - Clinical Development Pipeline
Table 10 6: Celldex Therapeutics - Clinical Development Pipeline
Table 10 7: CureVac - Clinical Development Pipeline
Table 10 8: Genexine - Clinical Development Pipeline
Table 10 9: GlobeImmune - Clinical Development Pipeline
Table 10 10: Gradalis - Clinical Development Pipeline
Table 10 11: Heat Biologics - Clinical Development Pipeline
Table 10 12: ISA Pharmaceuticals - Clinical Development Pipeline
Table 10 13: ISA101-CervISA - Clinical Study Analysis
Table 10 14: NewLink Genetics - Clinical Development Pipeline
Table 10 15: Northwest Biotherapeutics - Clinical Development Pipeline
Table 10 16: NovaRx - Clinical Development Pipeline
Table 10 17: Sotio - Clinical Development Pipeline
Table 10 18: Transgene - Clinical Development Pipeline
Table 10 19: UbiVac - Clinical Development Pipeline
Table 10 20: Vaccinogen - ACTIVE Clinical Trial Analysis
Table 10 21: Vaxon Biotech - Clinical Developmet Pipeline
Table 11 1: Global - Total Future Deaths Averted through Vaccination (Million), 2011 - 2020
Table 11 2: Global Goal-Level Indicators, 2015 & 2020
Table 11 3: Improvement Strategies or Requirements - the Joint Commission and the Project’s Collaborating Organizations
